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Humans beings have an intrinsic need to extract predict-
ability from apparent chaos, like the weather. Weather
reports consequently take various forms: 1) based on all
available current meteorological data, what is the estimated
probability of rain next Saturday morning (when I am
supposed to play golf)? 2) summarizing and comparing
trends and variances, how does last month’s rainfall compare
to what we usually expect for July in Boston? In the world
of coronary intervention, the analogous questions are as
follows: 1) what is the chance that Mrs. Jones is going to die
during her planned procedure or before hospital discharge?
2) how do the outcomes of her interventionalist (Dr. Smith)
compare with those of other good interventionalists treating
a similar mix of cases (the latter question now known as
“score-card” medicine)? Once these models are established
and an increased risk is anticipated, it is reasonable to also
ask, “given the increased risks in this case, what can I do
differently to prevent or attenuate the anticipated
complications?”
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Even in the earliest years of coronary angioplasty, An-
dreas Gruntzig established the precedent of collecting de-
tailed demographic and angiographic data as well as short-
and long-term procedural outcomes of his patients. As the
number of coronary interventions increased in the mid- and
late 1980s, such data collection continued and was used to
populate databases whose summary outcomes could be
examined. The availability of personal computers and pow-
erful statistical tools then allowed these databases to be
examined in greater detail to identify correlates of particular
outcomes of interest. In fact, the very evolution of modern
percutaneous intervention has been driven by the informa-
tion gained from these clinical databases, whether large
single-center experiences, regional registries, medical society
or government-sponsored initiatives, or multi-center clinical
trials. The extent to which we are able to properly measure
this type of data and use our analysis to drive improvements
in practice will determine whether the quality of care and
the outcome after percutaneous coronary intervention (PCI)
will continue to improve.
The study by Qureshi et al. (1) in this issue of the Journal
is the latest in that series of efforts that concentrate on
defining the most important clinical variables for predicting
the single most important adverse outcome: in-hospital
death. The facts are familiar: the overall mortality is 1.3%,
but there are some factors (acute myocardial infarction
[MI], age, multi-vessel disease, and baseline renal dysfunc-
tion) whose presence separately or in combination increases
the likelihood of death to 30% and whose absence reduces
the risk of mortality to 0.2%. What uses can we expect to
make from this model, and how does it differ from earlier
models?
The role of outcomes databases. The value of any such
model depends on many factors: the number of patients, the
detail and quality control of data collection (baseline,
procedural, and outcome), the completeness of ascertain-
ment (particularly of short-term and follow-up outcome
events), referral biases that strongly affect outcome (e.g., a
regional cardiogenic shock center vs. an elective-only cen-
ter), the quality of the operators, and the interventional tools
available during the data collection period. In a field with
rapidly evolving device and pharmacologic treatment strat-
egies, such as interventional cardiology over the past decade,
these questions are of great importance. In fact, our current
expectations with drug-eluting stents, distal embolic protec-
tion, and glycoprotein IIb/IIIa blockers (success 98%,
major complications 3%, late recurrence 7%) would
seem utterly fantastic to an interventionalist in 1990 or even
1995.
Of equal importance are the statistical tools used to
analyze the dataset and a clear understanding of their
robustness for the particular forecasting uses that are
planned. Published estimates of risk for an individual
patient may aid the patient and family in the consenting
process or assist the operator in selecting or avoiding specific
devices or adjunctive pharmacotherapy. The certainty of this
type of prediction, however, is limited if there are differences
between the model set and the patients to whom the model
is being applied (some differences not being fully captured in
standard angiographic and clinical variables) or if there are
other statistical issues such as sampling variability and
random variability in operator performance. These limita-
tions are of particular concern when the model is going to be
used to provide a performance “scorecard” for other opera-
tors.
Developing a risk prediction model. The general strategy
of the risk-prediction process includes having access to a
large, detailed, and relatively contemporaneous dataset and
understanding its intrinsic limitations (which variables were
collected, whether they were ascertained in all patients,
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whether data coding used uniform definitions and unbiased
collection agents, whether angiographic data were evaluated
by the operators or by a core laboratory, and so forth). A
classic multi-variable model requires that a relatively small
number of pre-specified potential risk factors be selected
based on clinical logic (too many candidate variables or post
hoc selection of such variables increases the risk to type 1
[false positive] results). Because these variables may be
related to each other (e.g., congestive heart failure, left
ventricular function, previous MI), careful multivariable
modeling should then be used to identify which remain as
independent predictors after adjustments are made for all
other variables in the model.
The currently available models have good utility, but each
has some level of limitation (2–9). Several were developed
within single centers (6,8,9), specialized centers (4), or
particular geographic regions (2,5) and thus may have
limited generalizability to other populations. Many years
may elapse between the collection of data, analysis, and
eventual publication, compromising applicability to con-
temporary practice by the time the results are available.
Moreover, robust models require a large sample size to
predict outcomes that occur infrequently. For in-hospital
mortality after PCI, a 10,000-patient database with a 1.5%
overall mortality has only 150 events, which limits the
number of variables it can test (roughly 20 events are
required for each variable tested). Most of the databases
used for model development and validation have thus
included far too few patients for complex models of mor-
tality prediction.
The quality of any model must also be measured carefully.
A model that is constructed using a given population (the
test set) is then validated by testing the model either in
another portion of the same database—by jack-knifing or
bootstrapping—or in a separate external database (the
validation set). These procedures reduce the chance that a
detected predictor was due to a unique property of the test
set rather than being a robust predictor. The statistical
quality of the proposed models relies on two measures
regarded as measures of quality: discrimination and
goodness-of-fit. Discrimination is usually measured by the c
statistic. This reflects the area under the receiver-operating
curve and thus is a measure of the model’s ability to assign
true positive outcomes as opposed to false positives. Models
with a c statistic approaching 1 have perfect discrimination
with a false-positive rate of 0% and a true-positive rate or
sensitivity of 100%. Logistic regression models with c
statistics in the range of 0.80 are usually considered to have
high discriminatory ability, but this means that the model
will still miss 20% of the patients with that adverse event. In
fact, it would be only slightly better than a model with no
discriminatory ability, which has an area under the received
operating curve or straight line of 0.50! The goodness-of-fit is
frequently assessed using the Hosmer-Lemeshow test,
which determines the difference between the event rate
predicted by the model and the observed rate. A p value
0.1 usually indicates that the model provides a good fit for
the data and that differences are not statistically different,
but it does not exclude potentially clinically significant
differences between observed and predicted outcomes.
Therefore, high scores for discrimination and goodness of fit do
not necessarily mean that the model has high predictive accuracy
for individual patients. A mortality predictor model for a
population of 10,000 patients may thus predict a mortality
of 10% for the highest decile, but even with a perfect fit, we
do not know which 100 of those 1,000 patients will die.
The good news is that the available PCI mortality models
provide some reassuring features despite these inherent
limitations. First, each of the models included in Table 1
does have high discriminatory and goodness-of-fit scores.
Second, even though the models represent patients from
different eras and various populations, their strongest pre-
Table 1. Multivariable Predictors of Mortality in Various Published Interventional Models
First author Hannan Kimmel Ellis O’Connor Moscucci Shaw Qureshi
Database source New York SCAI 5 U.S. hospitals NNE 8 Michigan hospitals ACC-NCDR Beaumont
Years of treatment 1991–1994 1992 1993–1994 1994–1996 1997–1999 1998–2000 1996–1998
Number of patients 62,670 10,622 12,985 15,331 10,729 100,253 9,954
Age X X X X X X X
MI 24 h X X X X X X X (14 days)
Shock X X X X X X
LV function X X X X
Female X X X
Lesion complexity X X X X
Diabetes X X
Renal failure X X X X X
Left main disease X
Proximal LAD X
Urgent procedure X X
Pre-procedure IABP X X
PVD X X X
Multivessel disease X X X
For each model, the multivariable correlates of mortality found are indicated by an “X”.
ACC-NCDR  American College of Cardiology-National Cardiovascular Device Registry; IABP  intra-aortic balloon pump; LAD  left anterior descending; LV  left
ventricular; MI  myocardial infarction, NNE  Northern New England; PVD  peripheral vascular disease; SCAI  Society for Cardiac Angiography and Intervention.
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dictors are remarkably consistent and relate mostly to patient
rather than technical variables. This has been substantiated
in a recent report from the National Heart, Lung, and
Blood Institute dynamic registry (NHLBI), in which three
of the five tested models developed in the pre-stent era
(New York State, Northern New England Cooperative
Group, and Cleveland Clinic Foundation) showed excellent
correlation for predicted and observed mortality among
patients in the NHLBI database treated between 1997 and
1999 (10). This is somewhat less certain for angiographic
lesion factors, however, because many of the lesion charac-
teristics in the American College of Cardiology/American
Heart Association classification scheme (e.g., lesion eccen-
tricity) have been eliminated as technology has improved.
Also, some of the remaining angiographic variables are
actually surrogates for basic clinical variables (e.g., recent
total occlusion is a surrogate for acute MI) (8).
The model presented by Qureshi et al. (1) is simple
enough to use at the bedside, appears to be useful for
forecasting procedural risk for some important patient
groups, and has high discriminatory ability and calibration.
Knowing that a patient is in the highest risk group, whose
expected mortality is 10 times higher than the lowest risk
group, may be useful in giving patients and families a more
refined risk estimate than the routinely quoted “1% mortal-
ity” and may assist the operator in making decisions regard-
ing the use of certain therapeutic options.
But knowledge of the most reliable predictors should also
allow comparison of outcomes observed for different oper-
ators or hospitals to the outcomes expected based on the
predictive model. This would ideally allow appropriate and
complete adjustment of the treated population for signifi-
cant differences in baseline risk, and thus allow fair com-
parisons between operators or hospitals (the rainfall in July
question). There are several concerns, however, with using
this model for comparing different operators and hospitals
in a scorecard fashion. The boundary selected by Qureshi
for each of the four variables is arbitrary and does not
delineate among various levels of increased risk. For exam-
ple, although patients over age 65 are at higher risk, this risk
is certainly higher for an 86-year-old than a 66-year-old
patient. Likewise, no one would question a higher overall
risk for patients with MI within 14 days, but the highest-
risk patients would be those being treated for acute MI
within 24 h, particularly if they have hemodynamic insta-
bility. Similar arguments can be made for the other two
variables of creatinine 1.5 mg/dl and multi-vessel disease,
which the model considers as unqualified binary variables.
This considerable degree of smoothing of the overall risk
curve by using these dichotomous cutoffs may lead to a
systematic underestimation of the risk for the truly high-risk
patient and a significant overestimation of the risk for many
other patients, thus failing to adjust adequately for higher-
or lower-risk cohorts across operators and hospitals for
which the distribution of variable values may differ from the
test set.
Risk adjustment models, scorecards, and quality im-
provement. Although such simplified risk predictor mod-
els for scoring individual patients may have limited utility
beyond what an experienced clinician can surmise using
even less complex methods of clinical assessment, the future
for true risk-adjustment models appears much brighter.
Keeping performance scores of individual operators or,
more commonly, for institutions has been of increasing
interest over the past 10 to 15 years, following the lead of
cardiac surgery. Even though such scoring systems are
initiated for the purpose of quality assessment and improve-
ment, public reporting of results and the dissemination of
provider rankings add an element of fear and anxiety for
many providers, if data unadjusted for risk are published, as
they were by Medicare for coronary artery bypass grafting
surgery in 1987. This underscores the importance of using
the most refined and scientifically valid methods for risk
adjustment.
Unfortunately, even the best and most sophisticated
multiple regression models developed for the purpose of risk
adjustment have serious deficiencies and limitations, as
discussed previously. Moreover, even the best models can-
not compensate for the smaller sample sizes present at the
institution or operator level and the associated statistical
uncertainty. The wide resulting confidence intervals make it
virtually impossible to provide any meaningful estimation of
appropriateness of outcome for the low-volume operator or
institution. A low-volume operator may look very good or
very bad depending on how his or her last case went, and
such models cannot fully correct for all confounders of risk
in a small sample size. There are additional problems, such
as failure to account for sampling variability, unmeasured
confounding, and random variability (noise) between oper-
ators that are not fully correctable by any model, so that
when resulting data are disclosed publicly, any risk-adjustment
effort must be viewed as imperfect rather than as a true leveling
of the playing field.
Given these significant problems with multiple regression
models, Shahian et al. (11) have suggested the use of
hierarchical or random-effect models for risk adjustment
among cardiac surgery providers. The hierarchical models
reduce the overly optimistic precision estimates by attempt-
ing to adjust for confounding by variances in treatment
decisions between physicians and patients in the predictor
dataset. Accounting for random operator effects dampens
variability toward the mean and thereby provides more
reliable estimates (12). Although they are much more
complex, they are not beyond the capacity of groups
involved in the risk-adjustment exercise.
In summary, the objective for any risk-prediction or
adjustment tool should be to foster continuous quality
improvement. Although simple bedside scoring as proposed
by Qureshi et al. (1) may be of some use for classifying
patients into broad risk categories, the ramifications of
bona-fide risk adjustment demand more complex systems.
Public presentation of the results must be undertaken
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cautiously and with adequate explanation of limitations to
avoid unnecessary punitive components that might lead to
gaming of the system (e.g., by avoiding high-risk cases,
which may deny benefit to the patients with the most to
gain from a high-quality procedure). Although the tracking
of performance scores within individual centers and the
comparisons with regional or national standards are desir-
able, those centers should also implement the minimum
volume standards that have been shown to be reasonable, if
not perfect, surrogates for performance quality (4,13). Fi-
nally, it is not clear whether mortality is the appropriate
outcome measure, given its low frequency and the increasing
difficulty in predicting risk as the frequency of the studied
event diminishes. Other ways of measuring the success of a
procedure and sound judgment, rather than the natural
history of an acute illness, may be more useful. Physician-
led continuous quality improvement initiatives that include
the reporting of specified measurements of the success of a
procedure have been effective in cardiac surgery (14). Re-
gardless of the statistical methods used, however, the goal of
continuous quality improvement is essential to our deliver-
ing the brightest forecast for the safety of our interventional
cardiology patients.
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